Skip to main content
SpringerLink
Log in

Overview of Metronomic Chemotherapy in SWOG Breast Cancer Cooperative Group Clinical Trials

  • Chapter
  • First Online:
Metronomic Chemotherapy

  • 710 Accesses

Abstract

Metronomic chemotherapy, defined as continuous or frequent treatment with low doses of anticancer drugs, has been observed to provide excellent safety profiles and has been tested in many tumors. SWOG, formerly the Southwest Oncology Group, has reported extensively on metronomic chemotherapy used in breast cancer. The earliest trials reported on a continuous, or “Cooper-” type, Cyclophosphamide, Methotrexate, 5-Fluorouracil (CMF) regimen in the setting of adjuvant chemotherapy for node-positive breast cancer, in which cyclophosphamide is administered orally on a daily basis and the 5-FU and methotrexate are given by weekly intravenous injection. Subsequently, other regimens have been evaluated. We will, hereby, provide an overview of the main SWOG trials evaluating metronomic chemotherapy in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Romiti A, Cox MC, Sarcina I, Di Rocco R et al (2013) Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 72(1):13–33

    Article  CAS  PubMed  Google Scholar 

  2. Osborne CK, Rivkin SE, McDivitt RW et al (1986) Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr (1):71–74

    Google Scholar 

  3. Glucksberg H, Rivkin SE, Rasmussen S et al (1982) Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer 50(3):423–434

    Article  CAS  PubMed  Google Scholar 

  4. Rivkin SE, Green S, Metch B et al (1989) Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. J Clin Oncol 7:1229–1238

    CAS  PubMed  Google Scholar 

  5. Rivkin SE, Green S, Metch B et al (1993) One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol 11(9):1710–1716

    CAS  PubMed  Google Scholar 

  6. Rivkin SE, Green S, Metch B, Cruz AB et al (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12(10):2078–2085

    CAS  PubMed  Google Scholar 

  7. Rivkin SE, Green S, O’Sullivan J et al (1996) Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 14(1):46–51

    CAS  PubMed  Google Scholar 

  8. Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23(33):8313–8321

    Article  CAS  PubMed  Google Scholar 

  9. Ellis GK, Barlow WE, Gralow JR et al (2011) Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29(8):1014–1021

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Budd GT, Green S, O’Bryan RM et al (1995) Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol 13(4):831–839

    CAS  PubMed  Google Scholar 

  11. Budd TG, Barlow WE, Moore H. et al (2013) S0221: comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31(suppl):abstr CRA1008

    Google Scholar 

  12. Wood WC, Rafla S, Silver RT, Carey RW, Lesnick GJ et al (1985) A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB study. World J Surg 9(5):714–718

    Article  CAS  PubMed  Google Scholar 

  13. Mathe G, Plagne R, Morice V, Misset JL (1987) Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer. In: Salmon SE (ed) Adjuvant chemotherapy for cancer V. Grune & Stratton, Orlando, pp 271–280

    Google Scholar 

  14. Fisher B, Redmond CK, Wolmark N (1987) Long-term results from NSABP trials of adjuvant therapy for breast cancer. In: Salmon SE (ed) Adjuvant chemotherapy for cancer V. Grune & Stratton, Orlando, pp 283–295

    Google Scholar 

  15. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483–1496

    CAS  PubMed  Google Scholar 

  16. Ellis G, Livingston RB (1993) Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer. Cancer 71(2):392–396

    Article  CAS  PubMed  Google Scholar 

  17. Ellis GK, Livingston RB (1994) Augmented dose intensity with concurrent G-CSF and continuous 5-FU, Adriamycin and cyclophosphamide (FAC) chemotherapy for breast cancer. Proc ASCO 13:53

    Google Scholar 

  18. Ellis GK, Livingston RB, Gralow JR et al (2002) Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20(17):3637–3643

    Article  CAS  PubMed  Google Scholar 

  19. Ellis G, Green S, Livingston R et al (2000) Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a Southwest Oncology Group phase II study. Proc Am Soc Clin Oncol 19(suppl):85a, abstr 326

    Google Scholar 

  20. Bear H, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174

    Article  CAS  PubMed  Google Scholar 

  21. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983–5992

    Article  CAS  PubMed  Google Scholar 

  22. Henderson C, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983

    Article  CAS  PubMed  Google Scholar 

  23. Budd TG, Barlow WE, Moore H et al (2011) First analysis of SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early breast cancer. J Clin Oncol 29(suppl):abstr 1004

    Google Scholar 

  24. Nahleh Z (principal investigator). S0800 paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer. http://clinicaltrials.gov/ct2/show/NCT00856492

  25. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Wild R, Dings R, Subramanian I et al (2004) Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 110(3):343–351

    Article  CAS  PubMed  Google Scholar 

  27. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Natori T, Sata M, Washida M et al (2002) G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297:1058–1061

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center – Paul L. Foster School of Medicine, 4800 Alberta Avenue, El Paso, TX, 79905, USA

    Zeina A. Nahleh

Authors
  1. Zeina A. Nahleh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zeina A. Nahleh .

Editor information

Editors and Affiliations

  1. Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Guido Bocci

  2. Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA

    Giulio Francia

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nahleh, Z.A. (2014). Overview of Metronomic Chemotherapy in SWOG Breast Cancer Cooperative Group Clinical Trials. In: Bocci, G., Francia, G. (eds) Metronomic Chemotherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43604-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation